Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (154)
  • Open Access


    Diagnostic Performance of Serum miR-586 and miR-493 in Patients with Osteosarcoma

    Hao Dang*

    Oncologie, Vol.22, No.1, pp. 35-42, 2020, DOI:10.32604/oncologie.2020.012485

    Abstract This study aimed to explore the expression and diagnostic performance of miR-586 and miR-493 in patients with osteosarcoma. We enrolled 63 patients with osteosarcoma treated between May 2016 and May 2019 as the experimental group and 55 healthy volunteers who underwent physical examination during the same period as the control group. We detected miR-586 and miR-493 expression in serum, normal bone tissue, and tumor samples. We also evaluated the relationship between clinical indicators and the miR-586 and miR-493 expression levels. The correlation between the serum and osteosarcoma tissue expression of miR-586 and miR-493 was examined… More >

  • Open Access


    Expression Changes, Prognostic Analysis and Risk Factors of miR-625-3p and miR-449a in Osteosarcoma Patients after Surgery

    Hui Zhang, Zhan Wang, Lin Liu, Fuqiang Zhang, Yuxin Song, Yaowen Qian*

    Oncologie, Vol.22, No.1, pp. 23-33, 2020, DOI:10.32604/oncologie.2020.012493

    Abstract The expression changes of miR-625-3p and miR-449a in osteosarcoma patients after surgery is the critical study in this paper. Analysis of their prognosis and risk factors can be helpful in understanding the prognostic value for clinical purposes. Fifty-eight patients with osteosarcoma diagnosed in our hospital were considered as the research group (RG), and 52 health subjects at the same time were collected as the control group (CG). Fluorescence quantitative PCR (RTPCR) was employed to test the expression levels of miR-625-3p and miR-449a in the serum of subjects in both groups before surgery and patients in… More >

  • Open Access


    Effects of Dexmedetomidine Combined with Remifentanil Anesthesia and Propofol Combined with Remifentanil Anesthesia on Perioperative Inflammatory Response and Pulmonary Function in Patients with Lung Cancer

    Siqiang Tian1,#, Yao Jiang2,#, Ying Wang1, Jie Song1,*

    Oncologie, Vol.22, No.1, pp. 13-21, 2020, DOI:10.32604/oncologie.2020.012492

    Abstract To explore the effects of dexmedetomidine combined with remifentanil anesthesia and propofol combined with remifentanil anesthesia on perioperative inflammatory response and pulmonary function in patients with lung cancer. Totally 128 patients admitted to our hospital for lung cancer surgery were taken as the research object of this experiment. Among them, 67 cases were sedated with dexmedetomidine combined with remifentanil (Group A), and 61 cases were sedated with propofol combined with remifentanil (Group B). The changes of vital signs, respiratory interval (RR), blood oxygen saturation (SpO2) and blood sugar before and after sedation were recorded. The… More >

  • Open Access


    Sinomenium Inhibits the Viability of Hepatoma Carcinoma Cells through Activating IFNA2

    Jingjing He1,2, Lingyi Zhang2, Dan Guo3, Xingwen Han4, Hui Zhang5, Liang Wang2, Youcheng Zhang1,*

    Oncologie, Vol.22, No.1, pp. 1-12, 2020, DOI:10.32604/oncologie.2020.012436

    Abstract Hepatocellular carcinoma (HCC) ranks the sixth place of most common cancers. Meanwhile, it is the tertiary mortality cause of cancer. There is no effective therapeutic method to prevent and treat the liver cancer. Sinomenine is a kind of Chinese traditional medicine herbal, it is reported that it can inhibit the viability of several cancer cells. The study is to explore whether sinomenine is also able to inhibit the cell viability of HCC and its potential mechanism. The IC50 of sinomenine in BEL-7402 cells was 5.351 mmol/L, and the IC50 of sinomenine in SMMC-7721 cells was… More >

Displaying 151-160 on page 16 of 154. Per Page